Abstract Library

#661 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Carcinoid Syndrome: Results of a Phase 2, Multicenter, Open-label, Serial-Ascending Study

Introduction: Excess serotonin (5-HT) in patients (pts) with carcinoid syndrome (CS) is associated with symptoms including increased bowel movement (BM) frequency.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Pavel M, Wiedenmann B, Caplin M, Hörsch D, Freiman J,

Keywords: symptom relief, diarrhea,

#396 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Symptomatic Carcinoid Syndrome: Preliminary Results of an Ongoing Phase 2, Multicenter, Open-label, Serial-ascending, European Study

Introduction: Excess serotonin (5-HT) may cause gastrointestinal (GI) symptoms (e.g., diarrhea) in carcinoid syndrome (CS) patients. Telotristat etiprate is an oral serotonin synthesis inhibitor designed to reduce peripheral 5-HT levels and alleviate GI distress.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Pavel M, Wiedenmann B, Seufferlein T, Freiman J, Law L,

Keywords: carcinoid syndrome, telotristat etiprate ,

#394 Efficacy of Telotristat Etiprate in Refractory Carcinoid Syndrome: Results of a Randomized, Placebo-controlled, Multicenter Study

Introduction: Diarrhea associated with carcinoid syndrome (CS) has been attributed to excess serotonin. Telotristat etiprate is an oral serotonin synthesis inhibitor that decreases peripheral serotonin production.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulke M, O'Dorisio T, Phan A, Bergsland E, Freiman J,

Keywords: carcinoid syndrome, telotristat etiprate,